- $128.21m
- -$54.56m
U.S. RESEARCH ROUNDUP-Darden Restaurants, Fedex, Nike
Brief: Nkarta Q4 Net Income USD -27.754 Million
Nkarta Inc expected to post a loss of 59 cents a share - Earnings Preview
Brief: Boxer Capital Reports 9.0% Passive Stake In Nkarta
CAR-T therapy developers fall amid U.S. FDA investigation
Nkarta Inc expected to post a loss of 67 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Evelo Biosciences, Nkarta, O'Reilly Automotive
U.S. STOCKS ON THE MOVE-DXC Technology, Nvidia, Lisata Therapeutics
Nkarta Inc reports results for the quarter ended in June - Earnings Summary
Brief: Nkarta Q2 Net Income USD -33.287 Million
Nkarta Inc expected to post a loss of 68 cents a share - Earnings Preview
Brief: Nkarta Appoints Alyssa Levin As CFO
Brief: Nkarta Updates Clinical Progress Of CAR-NK Cell Therapy For Patients With Relapsed, Refractory Acute Myeloid Leukemia
Brief: Nkarta Presents Nkx019 Clinical Data At The European Hematology Association 2023 Congress And 17Th International Conference On Malignant Lymphoma
Nkarta Inc reports results for the quarter ended in March - Earnings Summary
Brief: Nkarta Reports First Quarter 2023 Financial Results
Brief: Nkarta posts Q1 basic EPS USD -0.63
Nkarta Inc expected to post a loss of 70 cents a share - Earnings Preview
Brief: Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies And Combination Agents With Nk Cell-Based Therapies At The 2023 Aacr Annual Meeting